How many employees does Exelixis, Inc. have?

Exelixis, Inc. reported 1,077 employees for the fiscal year ending Jan 2026, in the annual report it filed on February 10, 2026. That is down 6.1% from a year earlier.

What is Exelixis, Inc.'s revenue per employee?

Exelixis, Inc. brought in $2.32B of revenue in fiscal Jan 2026, which is $2.15M per employee. That ranks 3 of 39 companies we track in Biotechnology, where the median is $602K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

Exelixis, Inc. employees and revenue per employee

EXEL · Biotechnology · $14.7B market cap

Exelixis, Inc. had 1,077 employees at the end of fiscal Jan 2026, down 6.1% from a year earlier. Revenue for the year was $2.32B, up 7.0% from a year earlier, or $2.15M per employee. Revenue held up or grew while headcount stayed flat or fell.

Employees

1,077

-6.1% YoY

Revenue

$2.32B

+7.0% YoY

Revenue / employee

$2.15M

Peer median $602K

Rank in industry

3 of 39

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2016

Hover a year for the numbers.

EXEL employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Jan 2026	1,077	$2.32B	$2.15M	-6.1%	+7.0%
Jan 2025	1,147	$2.17B	$1.89M	-12.4%	+18.5%
Dec 2023	1,310	$1.83B	$1.40M	+7.1%	+13.6%
Dec 2022	1,223	$1.61B	$1.32M	+28.2%	+12.3%
Dec 2021	954	$1.43B	$1.50M	+23.4%	+45.3%
Jan 2021	773	$988M	$1.28M	+25.3%	+2.0%
Jan 2020	617	$968M	$1.57M	+27.5%	+13.3%
Dec 2018	484	$854M	$1.76M	+30.1%	+88.7%
Dec 2017	372	$452M	$1.22M	+29.6%	+136.3%
Dec 2016	287	$191M	$667K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

Exelixis, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
HALO Halozyme Therapeutics, Inc.	423	$1.40B	$3.30M	Efficient growth
UTHR United Therapeutics Corporation	1,400	$3.18B	$2.27M	Efficient growth
EXEL Exelixis, Inc.	1,077	$2.32B	$2.15M	Leaner
PTCT PTC Therapeutics, Inc.	991	$1.73B	$1.75M	Efficient growth
ALNY Alnylam Pharmaceuticals, Inc.	2,500	$3.71B	$1.49M	Efficient growth
NBIX Neurocrine Biosciences, Inc.	2,000	$2.86B	$1.43M	Efficient growth
BMRN BioMarin Pharmaceutical Inc.	3,221	$3.22B	$1.00M	Efficient growth
MRNA Moderna, Inc.	4,700	$1.94B	$414K	Contracting
FTRE Fortrea Holdings Inc.	14,300	$2.72B	$190K	Leaner

Every Healthcare company

Questions about Exelixis, Inc.

How many employees does Exelixis, Inc. have?: Exelixis, Inc. reported 1,077 employees for the fiscal year ending Jan 2026, in the annual report it filed on February 10, 2026. That is down 6.1% from a year earlier.
What is Exelixis, Inc.'s revenue per employee?: Exelixis, Inc. brought in $2.32B of revenue in fiscal Jan 2026, which is $2.15M per employee. That ranks 3 of 39 companies we track in Biotechnology, where the median is $602K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare EXEL with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in Exelixis, Inc.'s annual reports (Form 10-K), latest filed February 10, 2026. This is data, not a recommendation to buy or sell EXEL.